StockNews.com Begins Coverage on NeuroMetrix (NASDAQ:NURO)

Equities research analysts at StockNews.com started coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research report issued to clients and investors on Monday. The firm set a “sell” rating on the medical device company’s stock.

NeuroMetrix Stock Performance

Shares of NURO opened at $4.00 on Monday. NeuroMetrix has a fifty-two week low of $2.66 and a fifty-two week high of $4.73. The stock has a fifty day moving average of $4.04 and a two-hundred day moving average of $3.89. The company has a market capitalization of $8.12 million, a PE ratio of -0.72 and a beta of 2.29.

NeuroMetrix (NASDAQ:NURO) last released its earnings results on Tuesday, August 6th. The medical device company reported ($0.74) EPS for the quarter. NeuroMetrix had a negative net margin of 181.04% and a negative return on equity of 41.74%. The business had revenue of $0.77 million during the quarter.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.